Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
Guillaume J
GJ
Besson
Deborah
D
McMahon
Frank
F
Maldarelli
John W
JW
Mellors
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D004279:DNA, Viral; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium